InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,978.00
(
-1.19%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.27
(
0.00%
)
Bitcoin
60,388.75
(
0.18%
)
Post# of 252336
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119911
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 141471

Monday, 05/07/2012 4:41:36 PM

Monday, May 07, 2012 4:41:36 PM

Post# of 252336

NVS—I don't think the withdrawal of NDA for SOM230 was related to the LAR formulation. The LAR formulation trial in Cushing's is few years behind and they still have ongoing trials with the S.C formulation my guess is NVS will re-file before with added data from those trials.

Thanks—that makes sense.

…[NVS] filed [SOM230] in the EU in late 2010 and approved in early 2012, isn't that a bit long?

Not unduly so, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up